Semaglutide Pen Injector

Phase 3

UUniversitaire Ziekenhuizen KU Leuven

Semaglutide Pen Injector is one of 63 therapeutic programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostate CancerActive, not recruiting

Opioid Use DisorderRecruiting

Diabetes Type1Recruiting

Prostate CancerPhase 3

Active, not recruiting

Opioid Use DisorderPhase 2

Recruiting

Diabetes Type1Phase 2

Recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Leuprorelin

Takeda

Phase 3

9 2

Xaluritamig

Amgen

Phase 3

4 3

AAA617

Novartis

Phase 3

2 4

Piflufolastat

Novartis

Phase 3

2 5

Semaglutide Pen Injector

UUniversitaire Ziekenhuizen KU Leuven

Phase 3

1 6

Gnrh Agonist/antagonist

NNorthwestern University

Phase 3

2 7

Luteinizing Hormone Releasing Hormone

UUS Department of Veterans Affairs

Phase 3

2 8

Piflufolastat F 18

Novartis

Phase 3

1 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Opioid Use Disorder

NCT06548490

Q4 2027

ApprovedActive, not recruiting

Prostate Cancer

NCT06908694

Q2 2028

Phase 2Recruiting

Diabetes Type1

NCT06411210

Q2 2030

Phase 3Recruiting

Glucose Intolerance

NCT05569772

Clinical

Trials by Indication[1]

Glucose intolerance1 trial

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT

Recruiting·UUniversitaire Ziekenhuizen KU Leuven·Phase 3·NCT05569772·252 enrolled

Prostate Cancer1 trial

GLP1-Receptor Agonists in Men With Prostate Cancer: Control of Cardiovascular Risk Factors and Prostate Biomarkers

Active, not recruiting·HHamilton Health Sciences Corporation·Approved·NCT06908694·20 enrolled

Opioid Use Disorder1 trial

GLP-1R Agonist Treatment for Opioid Use Disorder

Recruiting·MMilton S. Hershey Medical Center·Phase 2·NCT06548490·200 enrolled

Diabetes type11 trial

Obesity Complicating Type 1 Diabetes in Young Adults: Physiology and Impact of GLP-1 Analogue Anti-obesity Treatment on Cardiometabolic Risk Factors

Recruiting·YYale University·Phase 2·NCT06411210·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Semaglutide Pen Injector. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Semaglutide Pen Injector. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Universitaire Ziekenhuizen KU Leuven company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversitaire Ziekenhuizen KU Leuven

Semaglutide Pen Injector

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q2 2028

Q2 2030

Trials by Indication[1]

Glucose intolerance1 trial

Prostate Cancer1 trial

Opioid Use Disorder1 trial

Diabetes type11 trial

References

Drug Info

Quick Facts

Related News